{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:01:59Z","timestamp":1767142919150,"version":"build-2238731810"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11886-020-01374-2","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T02:02:32Z","timestamp":1596852152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-1282","authenticated-orcid":false,"given":"Augustus","family":"Hough","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Wearden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"1374_CR1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641\u201354.","journal-title":"Lancet"},{"key":"1374_CR2","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","volume":"67","author":"BW Perry","year":"2016","unstructured":"Perry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol. 2016;67:2941\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1374_CR3","first-page":"2872","volume":"73","author":"FL Ruderg","year":"2019","unstructured":"Ruderg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"12 Suppl 3","key":"1374_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","volume":"84","author":"JP Donnelly","year":"2017","unstructured":"Donnelly JP, Hanna M. Cardiac amyolidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl 3):12\u201326.","journal-title":"Cleve Clin J Med"},{"issue":"9","key":"1374_CR5","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006075.","journal-title":"Circ Heart Fail"},{"key":"1374_CR6","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585\u201394.","journal-title":"Eur Heart J"},{"key":"1374_CR7","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879\u201387.","journal-title":"Eur Heart J"},{"key":"1374_CR8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin cardiac amyloidosis. Circulation. 2012;126:1286\u2013300.","journal-title":"Circulation"},{"key":"1374_CR9","unstructured":"Tegsedi [package insert]. Boston: Akcea Therapeutics, Inc; 2019."},{"key":"1374_CR10","unstructured":"Onpattro [package insert]. Cambridge: Alnylam Pharmaceuticals, Inc; 2020."},{"key":"1374_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG, et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid. 2016;23:148\u201357.","journal-title":"Amyloid"},{"key":"1374_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22\u201331.","journal-title":"N Engl J Med"},{"key":"1374_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","volume":"10","author":"OB Suhr","year":"2015","unstructured":"Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10:109.","journal-title":"Orphanet J Rare Dis"},{"key":"1374_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"1374_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020;27:52\u20138.","journal-title":"Amyloid"},{"key":"1374_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis analysis of the APOLLO Study. Circulation. 2019;139:431\u201343.","journal-title":"Circulation"},{"key":"1374_CR17","unstructured":"24 Month open label study of the tolerability and efficacy of an antisense oligonucleotide (inotersen) in patients with transthyretin (ttr) amyloid cardiomyopathy \u2013 full text view- ClinicalTrials.gov [Internet]. [cited 2020 April 28]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03702829. Accessed 28 Apr 2020"},{"key":"1374_CR18","unstructured":"APOLLO-B: a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of patisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy) \u2013 full text view- ClinicalTrials.gov [Internet]. [cited 2020 April 28]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03997383. Accessed 28 Apr 2020"},{"issue":"Suppl 1","key":"1374_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/13506129.2011.574354073","volume":"18","author":"JL Berk","year":"2011","unstructured":"Berk JL, Dyck PJ, Obici L, Zeldenrust SR, Sekijima Y, Yamashita T, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid. 2011;18(Suppl 1):196\u20137.","journal-title":"Amyloid."},{"key":"1374_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/13506129.2014.997872","volume":"22","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22:79\u201383.","journal-title":"Amyloid."},{"key":"1374_CR21","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109:9629\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1374_CR22","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","volume":"583","author":"N Ferreira","year":"2009","unstructured":"Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, Bai G, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 2009;583:3569\u201376.","journal-title":"FEBS Lett"},{"issue":"3","key":"1374_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"1374_CR24","unstructured":"A phase 3, randomized, double-blind, placebo-controlled study of the efficacy and safety of AG10 in subjects with symptomatic transthyretin amyloid cardiomyopathy (ATTRIBUTE-CM) \u2013 full text view- ClinicalTrials.gov [Internet]. [cited 2020 April 28]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03860935. Accessed 28 Apr 2020"},{"key":"1374_CR25","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.2147\/DDDT.S96893","volume":"9","author":"F aus dem Siepen","year":"2015","unstructured":"aus dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther. 2015;9:6319\u201325.","journal-title":"Drug Des Devel Ther"},{"key":"1374_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","volume":"101","author":"AV Kristen","year":"2012","unstructured":"Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012;101:805\u201313.","journal-title":"Clin Res Cardiol"},{"key":"1374_CR27","unstructured":"Vyndaqel [package insert]. New York: Pfizer, Inc; 2020."},{"key":"1374_CR28","doi-asserted-by":"publisher","first-page":"e003815","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","volume":"10","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Merlini G, et al. Design and rationale of the phase 3 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail. 2017;10:e003815.","journal-title":"Circ Heart Fail"},{"key":"1374_CR29","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316 Randomized trial of tafamidis showing reduction in mortality with therapy creating foundation of current ATTR-CA therapy.","journal-title":"N Engl J Med"},{"key":"1374_CR30","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"DJ Gillmore","year":"2016","unstructured":"Gillmore DJ, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404\u201312 Study highlighting role for expanded non-biopsy ATTR-CA diagnosis strategy; includes processes for ruling out AL-CA as part ATTR-CA diagnosis.","journal-title":"Circulation"},{"key":"1374_CR31","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;141:00\u201300. https:\/\/doi.org\/10.1161\/CIR.0000000000000792. Contemporary scientific statement from the American Heart Association providing clinicians with updated diagnostic and treatment strategies.","DOI":"10.1161\/CIR.0000000000000792"},{"key":"1374_CR32","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141:1214\u201324.","journal-title":"Circulation."},{"key":"1374_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Edebe B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24:194\u2013204.","journal-title":"Amyloid."},{"key":"1374_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1096\/fj.05-4509com","volume":"20","author":"I Cardoso","year":"2006","unstructured":"Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006;20:234\u20139.","journal-title":"FASEB J"},{"key":"1374_CR35","first-page":"517","volume":"2008","author":"B Macedo","year":"1782","unstructured":"Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta. 1782;2008:517\u201322.","journal-title":"Biochim Biophys Acta"},{"key":"1374_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1479-5876-8-74","volume":"8","author":"I Cardoso","year":"2010","unstructured":"Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74.","journal-title":"J Transl Med"},{"issue":"Suppl 1","key":"1374_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/13506129.2012.678508","volume":"19","author":"L Obici","year":"2012","unstructured":"Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19(Suppl 1):34\u20136.","journal-title":"Amyloid."},{"key":"1374_CR38","unstructured":"A study of doxycycline and tauroursodeoxycholic acid (Doxy\/TUDCA) plus standard supportive therapy versus standard supportive therapy alone in cardiac amyloidosis caused by transthyretin \u2013 full text view- ClinicalTrials.gov [Internet]. [cited 2020 April 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03481972. Accessed 28 Apr 2020"},{"key":"1374_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","volume":"24","author":"J Wixner","year":"2017","unstructured":"Wixner J, Pilebro B, Lundgren HE, Olsson M, Anan I. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Amyloid. 2017;24:78\u20139.","journal-title":"Amyloid."},{"key":"1374_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","volume":"25","author":"E Karlstedt","year":"2019","unstructured":"Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM. Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail. 2019;25:147\u201353.","journal-title":"J Card Fail"},{"key":"1374_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93\u20137.","journal-title":"Nature."},{"key":"1374_CR42","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373:1106\u201314.","journal-title":"N Engl J Med"},{"key":"1374_CR43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","volume":"23","author":"JN Higaki","year":"2016","unstructured":"Higaki JN, Chakrabartty A, Galant NJ, Hadley KC, Hammerson B, Nijjar T, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid. 2016;23:86\u201397.","journal-title":"Amyloid."},{"key":"1374_CR44","unstructured":"A study of PRX004 in subjects with amyloid transthyretin (ATTR) Amyloidosis \u2013 full text view- ClinicalTrials.gov [Internet]. [cited 2020 April 20]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03336580. Accessed 20 Apr 2020"}],"updated-by":[{"DOI":"10.1007\/s11886-020-01426-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000}}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-01374-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-020-01374-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-01374-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T19:30:23Z","timestamp":1628364623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-020-01374-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1007\/s11886-020-01374-2","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,8]]},"assertion":[{"value":"8 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"On page 2 of the original publication, in the section on <b>TTR Silencers<\/b> dosing of patisiran in the APOLLO study was stated as being given every 3\ufffd\ufffdmonths; this is inaccurate as patisiran was dosed every 3\ufffd\ufffdweeks in the APOLLO study.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"106"}}